Sobi publishes its report for the first quarter 2017

Read more

Invitation – Presentation of Sobi’s Q1 2017 results

On 28 April, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the first quarter 2017.

Financial analysts and media...

Read more

Sobi publishes 2016 Annual Report

Read more

Sobi publishes 2016 Annual Report

Read more

Theresa Heggie resigns from the Board of Directors and will not be proposed for re-election at Sobi’s annual general meeting 2017

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Theresa Heggie has resigned from her position as Member of the Board of Directors,...

Read more

Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)

The shareholders in Swedish Orphan Biovitrum AB (publ) Reg. No. 556038-9321, are hereby summoned to the annual general meeting (the “Meeting”), to be...

Read more

Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)

The shareholders in Swedish Orphan Biovitrum AB (publ) Reg. No. 556038-9321, are hereby summoned to the annual general meeting (the “Meeting”), to be...

Read more

FDA approves in-use storage at room temperature for Orfadin® capsules

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that FDA has approved in-use storage at room temperature (25°C or less) for up to 45 days...

Read more

Long-term safety and efficacy extension study data of Alprolix® for haemophilia B published in Thrombosis and Haemostasis

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Bioverativ Inc. (NASDAQ: BIVVV) today announce that interim results from the B-YOND...

Read more

Sobi™ receives approval from the European Medicines Agency for higher capacity drug substance manufacturing for Elocta®

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has received approval from the European Medicines Agency (EMA) for the grouped type II 15 K...

Read more

Archive